(HealthDay)—Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma (HL) do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, ...
not rated yet |
0
(HealthDay)—Cognitive behavioral therapy (CBT) and physical exercise improve endocrine and urinary symptoms as well as physical functioning in patients with breast cancer treatment-induced menopause, according ...
not rated yet |
0
(HealthDay)—In survivors of childhood hematologic malignancies who have received allogeneic hematopoietic stem cell transplantation (alloHSCT), body mass index (BMI) decreases significantly, mainly due ...
2 / 5 (1) |
0
(HealthDay)—There are no statistically significant differences in the rates of local recurrence (LR), distant recurrence, relapse-free survival, overall survival, or late toxicity in patients treated with ...
not rated yet |
0
(HealthDay)—An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure (FFTF) or overall survival rate in selected patients with low-tumor burden follicular ...
5 / 5 (1) |
0
(Medical Xpress)—A drug which for decades has been widely used to treat pain related to cancer has no net clinical benefit, researchers in the Palliative Care Clinical Studies Collaborative (PaCCSC) based ...
3.7 / 5 (3) |
0
(HealthDay)—New evidence-based guidelines have been compiled on the management of fever and and neutropenia (FN) in children with cancer and/or who are undergoing hematopoietic stem-cell transplantation; ...
not rated yet |
0
(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of ...
not rated yet |
0
(HealthDay)—Using subcutaneously administered ketamine in a dose-escalating regimen as an adjunct to opioids and standard co-analgesics does not have any clinical benefit in relieving cancer pain, but it ...
not rated yet |
0
Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research ...
not rated yet |
0
(HealthDay)—Adult long-term survivors of childhood Hodgkin's lymphoma are at risk for neurocognitive impairment, according to research published online Sept. 4 in the Journal of Clinical Oncology.
5 / 5 (1) |
0
(HealthDay)—Patients with gastric and gastroesophageal junction (GEJ) cancer who survive for longer than three years after diagnosis seem to have distinct demographic and pathologic characteristics, compared ...
not rated yet |
0
(Medical Xpress)—A large meta-analysis conducted by researchers at Moffitt Cancer Center has concluded that breast cancer patients treated with chemotherapy are at risk for mild cognitive deficits after treatment. The meta-analysis, ...
not rated yet |
0
|
(HealthDay)—For children with metastatic MYCN-nonamplified neuroblastoma (NBL-NA) diagnosed at age 18 months or older, increased expression of tumor-associated inflammatory genes seems to correlate with p ...
5 / 5 (1) |
0
(HealthDay)—The monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, augments the antitumor activity of paclitaxel in patients with previously treated urothelial cancer, according ...
not rated yet |
0
